Sharon Lewin and Mark Dybul replace Jack Whitescarver and Françoise Barré-Sinoussi as cochairs of the advisory board.

The researchers studied a new compound that blocked a key viral protein that prompts infected cells to produce more virus.

Researchers discovered that higher levels of such cells were tied not only to infection risk but also HIV disease progression.

At stake in amfAR’s civil war is the nonprofit’s quest to find a cure for HIV.

This NIH study closely monitored 10 people with HIV who stopped antiretroviral treatment for weeks to months in a larger cure study.

CAR-T cells, which have recently made waves in the cancer field, may one day be the basis of a cure for HIV in humans.

Cure studies typically require a temporary break in HIV treatment, often with little promise of a personal benefit to the participant.

The small trial nevertheless provided researchers with clues to help in their quest for treatments that prompt viral remission.

Scientists reached this finding thanks to a highly precise means of sequencing HIV’s genetics.